2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

antineoplastic drugs

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131468
    Picoplatin

    AMD473; ZD0473

    		 DNA/RNA Synthesis Cancer
    Picoplatin (AMD473) is a platinum-based antineoplastic agent. Picoplatin is specifically to circumvent thiol-mediated drug resistance by sterically hindering its reaction with glutathione (GSH) while still retaining the ability to form cytotoxic lesions with DNA .
    Picoplatin
  • HY-147408
    Rezetecán

    SHR9265

    		 Topoisomerase ADC Cytotoxin Cancer
    Rezetecán (SHR9265) is a topoisomerase I inhibitor. In addition, Rezetecán can be used to synthesize Trastuzumab rezetecan, an antineoplastic agent. Rezetecán can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .
    Rezetecán
  • HY-17394
    Cisplatin
    530+ Cited Publications

    cis-Platinum; CDDP; cis-Diaminodichloroplatinum

    		 DNA Alkylator/Crosslinker Ferroptosis Autophagy Pyroptosis Lipoxygenase Cancer
    Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    Cisplatin
  • HY-B0245S
    Busulfan-d8

    		DNA Alkylator/Crosslinker Apoptosis Inflammation/Immunology Cancer
    Busulfan-d8 is a deuterium labeled Busulfan. Busulfan is a potent alkylating antineoplastic agent. Busulfan causes DNA damage by cross-linking DNAs and DNA and proteins. Busulfan inhibits thioredoxin reductase. Busulfan induces apoptosis. Busulfan is an immunosuppressive and myeloablative chemotherapeutic agent[1][2][3].
    Busulfan-d8
  • HY-B0245
    Busulfan
    10+ Cited Publications

    		 DNA Alkylator/Crosslinker Apoptosis Inflammation/Immunology Cancer
    Busulfan is a potent alkylating antineoplastic agent. Busulfan causes DNA damage by cross-linking DNAs and DNA and proteins. Busulfan inhibits thioredoxin reductase. Busulfan induces apoptosis. Busulfan is an immunosuppressive and myeloablative chemotherapeutic agent .
    Busulfan
  • HY-16372
    CP 461

    OSI-461

    		 Apoptosis Microtubule/Tubulin Cancer
    CP-461 (OSI-461) is a selective apoptotic antineoplastic drug (SAAND) by engaging tubulin on colchicine site
    CP 461
  • HY-152861
    Dazostinag

    TAK-676 free base

    		 STING Cancer
    Dazostinag (TAK-676 free base) is an agonist of stimulator of interferon genes (STING) protein with antineoplastic activity. Dazostinag can serve as a playload to synthesis antibody-drug conjugates (ADCs) .
    Dazostinag
  • HY-P99334
    Vorsetuzumab mafodotin

    Anti-Human CD70 Recombinant Antibody; SGN-75

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .
    Vorsetuzumab mafodotin
  • HY-13550A
    Ametantrone acetate

    NSC 196473 acetate; NSC 290813 acetate

    		 DNA/RNA Synthesis Cancer
    Ametantrone acetate (NSC 196473 acetate) is an antineoplastic drug with topoisomerase II inhibitory activity. Ametantrone acetate causes covalent cross-linking of DNA. The pharmacokinetic profile of Ametantrone acetate has been confirmed in clinical trials, and its elimination pathway in the body indicates the existence of a major metabolic pathway .
    Ametantrone acetate
  • HY-138627B
    AST5902 mesylate

    		EGFR Drug Metabolite Cancer
    AST5902 mesylate is a principal metabolite of Alflutinib, exhibiting significant antineoplastic activity. AST5902 mesylate contributes to the overall pharmacological effects in the treatment of non-small cell lung cancer. AST5902 mesylate is involved in the response to activating EGFR mutations and can help overcome EGFR T790M drug-resistant mutations.
    AST5902 mesylate
  • HY-U00279B
    Nitracrine hydrochloride

    		DNA/RNA Synthesis Cancer
    Nitracrine hydrochloride is a platinum-based antineoplastic drug with selective toxicity to hypoxic cells. Nitracrine hydrochloride exhibits significant cytotoxicity against the Chinese hamster ovary cell line AA8 under hypoxic conditions and is approximately 100,000 times more potent than misonidazole. Nitracrine hydrochloride exerts its effect by binding to the insertion of DNA and forming covalent adducts. The cytotoxicity of Nitracrine hydrochloride under hypoxic conditions is related to its reductive metabolism to form alkylated substances. At the same time, it may enhance the reactivity to DNA through the insertion of DNA, thereby improving the efficacy. Nitracrine hydrochloride can also inhibit RNA synthesis, contributing to its anti-tumor effect .
    Nitracrine hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: